Trial Profile

A Single Arm, Open-Label Phase I Study to Evaluate the Safety and Tolerability of ISC-hpNSC Injected Into the Striatum and Substantia Nigra of Patients With Parkinson's Disease

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 05 Apr 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ISC-hpNSC (Primary)
Indications Parkinson's disease
Focus Adverse reactions; First in man
Sponsors Cyto Therapeutics

Most Recent Events

03 Apr 2019 Planned End Date changed from 1 Dec 2019 to 1 Jun 2020.
03 Apr 2019 Planned primary completion date changed from 1 Sep 2019 to 1 Apr 2020.
03 Apr 2019 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com